KRAS and neoplasm: In many human tumours, including colorectal cancers, loss of function APC mutations co-occur with mutation in KRAS. We also exploited genetically engineered mice to assess whether the presence of a Kras mutation might modulate the effects of a tankyrase inhibitor/CDK4/6 inhibitor combination.